688192 logo

Dizal (Jiangsu) Pharmaceutical XSSC:688192 Stock Report

Last Price

CN¥47.65

Market Cap

CN¥19.8b

7D

7.4%

1Y

4.4%

Updated

07 Nov, 2024

Data

Company Financials +

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

XSSC:688192 Stock Report

Market Cap: CN¥19.8b

688192 Stock Overview

Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases.

688192 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dizal (Jiangsu) Pharmaceutical
Historical stock prices
Current Share PriceCN¥47.65
52 Week HighCN¥54.58
52 Week LowCN¥24.82
Beta0.27
11 Month Change-0.73%
3 Month Change23.03%
1 Year Change4.38%
33 Year Changen/a
5 Year Changen/a
Change since IPO-4.18%

Recent News & Updates

Recent updates

Shareholder Returns

688192CN BiotechsCN Market
7D7.4%6.5%5.8%
1Y4.4%-12.8%9.0%

Return vs Industry: 688192 exceeded the CN Biotechs industry which returned -16.2% over the past year.

Return vs Market: 688192 underperformed the CN Market which returned 5.9% over the past year.

Price Volatility

Is 688192's price volatile compared to industry and market?
688192 volatility
688192 Average Weekly Movement8.6%
Biotechs Industry Average Movement8.8%
Market Average Movement7.9%
10% most volatile stocks in CN Market12.0%
10% least volatile stocks in CN Market5.4%

Stable Share Price: 688192 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688192's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017807Zhang Xiaolinwww.dizalpharma.com

Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Fundamentals Summary

How do Dizal (Jiangsu) Pharmaceutical's earnings and revenue compare to its market cap?
688192 fundamental statistics
Market capCN¥19.81b
Earnings (TTM)-CN¥837.22m
Revenue (TTM)CN¥389.64m

50.8x

P/S Ratio

-23.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688192 income statement (TTM)
RevenueCN¥389.64m
Cost of RevenueCN¥13.65m
Gross ProfitCN¥375.99m
Other ExpensesCN¥1.21b
Earnings-CN¥837.22m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.01
Gross Margin96.50%
Net Profit Margin-214.87%
Debt/Equity Ratio197.6%

How did 688192 perform over the long term?

See historical performance and comparison